Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis

INTRODUCTION: Empagliflozin has demonstrated lower rates of cardiovascular outcomes vs. standard of care among patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). However, the impact of empagliflozin compared to other branded antihyperglycemic agents (AHAs) on total cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Raju, Aditya, Pimple, Pratik, Stafkey-Mailey, Dana, Farrelly, Eileen, Shetty, Sharash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776959/
https://www.ncbi.nlm.nih.gov/pubmed/34727356
http://dx.doi.org/10.1007/s13300-021-01173-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776959/
https://www.ncbi.nlm.nih.gov/pubmed/34727356
http://dx.doi.org/10.1007/s13300-021-01173-0

Ejemplares similares